A Phase 2 interventional study of EYP-1901 and Aflibercept 2mg/0.05mL Inj,Oph in Wet Age-related Macular Degeneration, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 67 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 127th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 138 in phase 2, and was the 512th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 161 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
EyePoint Pharmaceuticals, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
EyePoint Pharmaceuticals, Inc. has 4 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
This study is evaluating the 2 doses of EYP-1901 against aflibercept in a randomized study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EYP-1901 2060 mcg, single dose
Drug: EYP-1901
EYP-1901 3090 mcg, single dose
Drug: EYP-1901
Aflibercept 2 milligram (mg) \[0.05 milliliter (mL)\] every 8 weeks
Drug: Aflibercept 2mg/0.05mL Inj,Oph
Intravitreal Injection
Drug page: Aflibercept
Intravitreal Injection
Also known as: Eylea
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32
The BCVA was measured according to the standard procedure originally developed for Early Treatment Diabetic Retinopathy Study (ETDRS). The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 28 and 32
Change From Baseline in Best Corrected Visual Acuity up to Week 56
The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56
The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56
Supplemental therapy was any unscheduled injection of aflibercept, whether or not a subject had met rescue criteria. For the aflibercept arm, any aflibercept injection following Week 8 which did not occur at Weeks 16, 24, 32, 40, 48, or 56, was supplemental therapy. For either of the EYP-1901 arms, any aflibercept injection following the Week 8 visit was supplemental therapy.
Time frame: Weeks 32 and 56
Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8
Time to first supplemental aflibercept injection following Week 8 study treatment was defined as the date of the first supplemental aflibercept injection minus the date of the Week 8 study treatment administration, divided by 7 days per week. Subjects who did not receive any supplemental aflibercept injection following study treatment administration at Week 8 were censored at their date of last visit (those who completed) or date of last contact (those who discontinued the study early).
Time frame: From Week 8 to Week 56
Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose)
Normalized number of aflibercept injections including loading dose was calculated as (number of aflibercept injections received plus all loading doses received) / (time within study period in months), multiplied by 6 months (Week 32) or 12 months (Week 56).
Time frame: Weeks 32 and 56
Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT) up to Week 56
The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56
The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56
The percentage of subjects with no detectable intraretinal fluid/cysts in the central subfield were summarized by scheduled visit and for any time post-baseline visits. Intraretinal fluid was assessed for the categories 'Absent', 'Present, not clinically significant', 'Present, clinically significant' and 'Not Done'. If intraretinal fluid assessment at any scheduled visit fell under the category 'Absent or Present, not clinically significant', then it was considered as no detectable intraretinal fluid in that scheduled visit.
Time frame: Weeks 32 and 56
Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56
The total lesion area was defined as the active vascular component \[classic and occult choroidal neovascularization (CNV)\] and the non-vascular/fibrotic component (fibrosis, serous pigment epithelial detachment, elevated blocking hemorrhage or hyperplastic pigment). Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56
The total CNV area included the measured area of classic and occult components. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
Time frame: Baseline (Day 1) and Weeks 32 and 56
Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56
Blood samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.
Time frame: Up to Week 56
Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32
The AH samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.
Time frame: Up to Week 32
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to Week 56
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. An serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment. administration.
Time frame: From the study drug administration (Day 1) up to end of the study, approximately 56 weeks.
This Phase 2 prospective, randomized, double-masked study was conducted in previously treated subjects with wet age-related macular degeneration (wAMD) at 39 sites in the United States between 30 June 2022 and 24 April 2024.
| Milestone | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Started | 54 | 53 | 54 |
| Completed | 52 | 47 | 52 |
| Not completed | 2 | 6 | 2 |
| Withdrew: Adverse event: ocular - study eye | 0 | 1 | 0 |
| Withdrew: Adverse event: non-ocular | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Discontinued study without receiving study drug | 0 | 0 | 1 |
The BCVA was measured according to the standard procedure originally developed for Early Treatment Diabetic Retinopathy Study (ETDRS). The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| score on a scale | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 | 1.17 ± 0.830 | 1.05 ± 0.866 | 0.87 ± 0.841 |
The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| score on a scale | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Baseline (Day 1) | 73.4 ± 9.48 | 73.9 ± 7.90 | 74.9 ± 7.68 |
| Week 32 | 1.6 ± 6.81 | 1.0 ± 6.45 | 0.8 ± 5.22 |
| Week 56 | 1.1 ± 8.55 | 0.3 ± 8.10 | -1.9 ± 7.83 |
The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| percentage of subjects | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 32: >=5 BCVA Letter Gain | 34.0 | 25.0 | 21.2 |
| Week 32: >=5 BCVA Letter Loss | 13.2 | 20.8 | 11.5 |
| Week 32: >=10 BCVA Letter Gain | 5.7 | 10.4 | 5.8 |
| Week 32: >=10 BCVA Letter Loss | 5.7 | 6.3 | 3.8 |
| Week 32: >=15 BCVA Letter Gain | 1.9 | 2.1 | 0 |
| Week 32: >=15 BCVA Letter Loss | 1.9 | 0 | 1.9 |
| Week 56: >=5 BCVA Letter Gain | 32.7 | 23.4 | 15.4 |
| Week 56: >=5 BCVA Letter Loss | 23.1 | 23.4 | 32.7 |
| Week 56: >=10 BCVA Letter Gain | 17.3 | 12.8 | 3.8 |
| Week 56: >=10 BCVA Letter Loss | 11.5 | 10.6 | 13.5 |
| Week 56: >=15 BCVA Letter Gain | 1.9 | 4.3 | 0 |
| Week 56: >=15 BCVA Letter Loss | 7.7 | 4.3 | 3.8 |
Supplemental therapy was any unscheduled injection of aflibercept, whether or not a subject had met rescue criteria. For the aflibercept arm, any aflibercept injection following Week 8 which did not occur at Weeks 16, 24, 32, 40, 48, or 56, was supplemental therapy. For either of the EYP-1901 arms, any aflibercept injection following the Week 8 visit was supplemental therapy.
| percentage of subjects | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 32 | 94.3 | 62.5 | 63.5 |
| Week 56 | 82.7 | 42.6 | 46.2 |
Time to first supplemental aflibercept injection following Week 8 study treatment was defined as the date of the first supplemental aflibercept injection minus the date of the Week 8 study treatment administration, divided by 7 days per week. Subjects who did not receive any supplemental aflibercept injection following study treatment administration at Week 8 were censored at their date of last visit (those who completed) or date of last contact (those who discontinued the study early).
| week | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|
| Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8 | 37.00 (20.14 to NA) | 40.79 (20.00 to NA) |
Normalized number of aflibercept injections including loading dose was calculated as (number of aflibercept injections received plus all loading doses received) / (time within study period in months), multiplied by 6 months (Week 32) or 12 months (Week 56).
| normalized no. of aflibercept injections | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 32 | 3.23 ± 0.357 | 2.06 ± 0.583 | 2.13 ± 0.747 |
| Week 56 | 6.33 ± 0.754 | 3.45 ± 1.738 | 3.36 ± 1.854 |
The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| micron | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Baseline (Day 1) | 265.7 ± 39.86 | 264.5 ± 40.26 | 262.9 ± 34.46 |
| Week 32 | 5.4 ± 44.52 | 17.8 ± 42.27 | 10.6 ± 38.45 |
| Week 56 | 8.1 ± 58.33 | 12.2 ± 49.83 | 16.7 ± 51.98 |
The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| micron | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Baseline (Day 1) | 46.87 ± 27.753 | 49.84 ± 32.786 | 50.71 ± 28.507 |
| Week 32 | 33.05 ± 62.358 | 18.75 ± 48.197 | 10.68 ± 37.686 |
| Week 56 | 22.87 ± 69.509 | 39.50 ± 62.183 | 5.95 ± 38.866 |
The percentage of subjects with no detectable intraretinal fluid/cysts in the central subfield were summarized by scheduled visit and for any time post-baseline visits. Intraretinal fluid was assessed for the categories 'Absent', 'Present, not clinically significant', 'Present, clinically significant' and 'Not Done'. If intraretinal fluid assessment at any scheduled visit fell under the category 'Absent or Present, not clinically significant', then it was considered as no detectable intraretinal fluid in that scheduled visit.
| percentage of subjects | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 32 | 62.3 | 52.1 | 51.9 |
| Week 56 | 59.6 | 59.6 | 51.9 |
The total lesion area was defined as the active vascular component \[classic and occult choroidal neovascularization (CNV)\] and the non-vascular/fibrotic component (fibrosis, serous pigment epithelial detachment, elevated blocking hemorrhage or hyperplastic pigment). Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| millimeter square (mm^2) | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Baseline (Day 1) | 5.06884 ± 4.547571 | 5.48285 ± 5.488682 | 4.82169 ± 4.325932 |
| Week 32 | 1.24141 ± 2.862256 | 1.07111 ± 2.626369 | 1.13971 ± 2.024426 |
| Week 56 | 1.56516 ± 3.226403 | 1.84557 ± 4.174053 | 2.22914 ± 3.696873 |
The total CNV area included the measured area of classic and occult components. Baseline was defined as the last non-missing measurement before the initiation of study treatment.
| mm^2 | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Baseline (Day 1) | 5.06 ± 4.551 | 5.44 ± 5.531 | 4.77 ± 4.322 |
| Week 32 | 1.15 ± 2.968 | 1.10 ± 2.674 | 1.19 ± 2.033 |
| Week 56 | 1.46 ± 3.354 | 1.14 ± 5.345 | 2.31 ± 3.656 |
Blood samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.
| picogram per milliliter | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 8 - EYP-1901 concentration | — | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Week 8 - metabolite concentration | — | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 20 - EYP-1901 concentration | — | 23.206 ± 8.8871 | 27.121 ± 10.0821 |
| Week 20 - metabolite concentration | — | 1.01 ± 2.27 | 2.46 ± 3.86 |
| Week 32 - EYP-1901 concentration | — | 14.333 ± 6.1098 | 19.335 ± 7.3783 |
| Week 32 - metabolite concentration | — | 0.00 ± 0.00 | 0.598 ± 2.21 |
| Week 44 - EYP-1901 concentration | — | 10.292 ± 5.2086 | 14.180 ± 4.9819 |
| Week 44 - metabolite concentration | — | 0.00 ± 0.00 | 0.485 ± 1.69 |
| Week 56 - EYP-1901 concentration | — | 7.733 ± 4.9684 | 10.392 ± 5.2315 |
| Week 56 - metabolite concentration | — | 0.00 ± 0.00 | 0.121 ± 0.867 |
The AH samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.
| nanogram per milliliter | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Week 8 - EYP-1901 concentration | — | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Week 8 - metabolite concentration | — | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 20 - EYP-1901 concentration | — | 17.426 ± 13.7143 | 25.066 ± 18.8594 |
| Week 20 - metabolite concentration | — | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 32 - EYP-1901 concentration | — | 11.890 ± 10.8436 | 19.813 ± 15.0833 |
| Week 32 - metabolite concentration | — | 0.00 ± 0.00 | 0.00 ± 0.00 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. An serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment. administration.
| Participants | Aflibercept 2 mg - Study Eye | Aflibercept 2 mg - Fellow Eye | Aflibercept 2 mg - Systemic | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Fellow Eye | EYP-1901 2060 mcg - Systemic | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Fellow Eye | EYP-1901 3090 mcg - Systemic |
|---|---|---|---|---|---|---|---|---|---|
| any TEAEs | 30 | 21 | 40 | 30 | 11 | 28 | 30 | 20 | 39 |
| any Serious TEAEs | 2 | 1 | 6 | 0 | 0 | 6 | 4 | 0 | 9 |
Collected over TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2 mg - Study Eye | 0/54 (0%) | 2/54 (3.7%) | 30/54 (55.6%) |
| Aflibercept 2 mg - Fellow Eye | 0/54 (0%) | 1/54 (1.9%) | 17/54 (31.5%) |
| Aflibercept 2 mg - Systemic | 0/54 (0%) | 6/54 (11.1%) | 33/54 (61.1%) |
| EYP-1901 2060 mcg - Study Eye | 0/50 (0%) | 0/50 (0%) | 30/50 (60%) |
| EYP-1901 2060 mcg - Fellow Eye | 0/50 (0%) | 0/50 (0%) | 11/50 (22%) |
| EYP-1901 2060 mcg - Systemic | 2/50 (4%) | 6/50 (12%) | 28/50 (56%) |
| EYP-1901 3090 mcg - Study Eye | 0/52 (0%) | 4/52 (7.7%) | 30/52 (57.7%) |
| EYP-1901 3090 mcg - Fellow Eye | 0/52 (0%) | 0/52 (0%) | 20/52 (38.5%) |
| EYP-1901 3090 mcg - Systemic | 0/52 (0%) | 9/52 (17.3%) | 39/52 (75%) |
| Event | Aflibercept 2 mg - Study Eye | Aflibercept 2 mg - Fellow Eye | Aflibercept 2 mg - Systemic | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Fellow Eye | EYP-1901 2060 mcg - Systemic | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Fellow Eye | EYP-1901 3090 mcg - Systemic |
|---|---|---|---|---|---|---|---|---|---|
| EndophthalmitisInfections and infestations | 2/54 | 0/54 | 0/54 | 0/50 | 0/50 | 0/50 | 3/52 | 0/52 | 0/52 |
| Angina pectorisCardiac disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Cardiac arrestCardiac disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Cardiac failureCardiac disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Cardiac failure congestiveCardiac disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Gastric infectionInfections and infestations | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Septic shockInfections and infestations | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 0/52 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 1/50 | 0/52 | 0/52 | 1/52 |
| Supraventricular tachycardiaCardiac disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 0/50 | 0/52 | 0/52 | 1/52 |
| Non-infectious endophthalmitisEye disorders | 0/54 | 0/54 | 0/54 | 0/50 | 0/50 | 0/50 | 1/52 | 0/52 | 0/52 |
| Event | Aflibercept 2 mg - Study Eye | Aflibercept 2 mg - Fellow Eye | Aflibercept 2 mg - Systemic | EYP-1901 2060 mcg - Study Eye | EYP-1901 2060 mcg - Fellow Eye | EYP-1901 2060 mcg - Systemic | EYP-1901 3090 mcg - Study Eye | EYP-1901 3090 mcg - Fellow Eye | EYP-1901 3090 mcg - Systemic |
|---|---|---|---|---|---|---|---|---|---|
| Visual acuity reducedEye disorders | 3/54 | 2/54 | 0/54 | 1/50 | 2/50 | 0/50 | 8/52 | 2/52 | 0/52 |
| Urinary tract infectionInfections and infestations | 0/54 | 0/54 | 3/54 | 0/50 | 0/50 | 5/50 | 0/52 | 0/52 | 8/52 |
| HypertensionVascular disorders | 0/54 | 0/54 | 4/54 | 0/50 | 0/50 | 2/50 | 0/52 | 0/52 | 7/52 |
| COVID-19Infections and infestations | 0/54 | 0/54 | 7/54 | 0/50 | 0/50 | 5/50 | 0/52 | 0/52 | 5/52 |
| Conjunctival haemorrhageEye disorders | 4/54 | 1/54 | 0/54 | 6/50 | 1/50 | 0/50 | 3/52 | 0/52 | 0/52 |
| Subretinal fluidEye disorders | 4/54 | 0/54 | 0/54 | 6/50 | 0/50 | 0/50 | 3/52 | 0/52 | 0/52 |
| Retinal haemorrhageEye disorders | 1/54 | 3/54 | 0/54 | 2/50 | 0/50 | 0/50 | 6/52 | 1/52 | 0/52 |
| Vitreous floatersEye disorders | 1/54 | 0/54 | 0/54 | 2/50 | 2/50 | 0/50 | 6/52 | 1/52 | 0/52 |
| CataractEye disorders | 5/54 | 2/54 | 0/54 | 4/50 | 2/50 | 0/50 | 5/52 | 5/52 | 0/52 |
| Posterior capsule opacificationEye disorders | 0/54 | 1/54 | 0/54 | 4/50 | 2/50 | 0/50 | 1/52 | 2/52 | 0/52 |
Full Analysis Set (FAS) included all randomized subjects who received at least 1 dose of study treatment.
| Age, Continuous(years) | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Mean | 75.9 ± 7.59 | 76.4 ± 6.66 | 75.4 ± 7.19 | 75.9 ± 7.14 |
| Sex: Female, Male(Participants) | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Female | 29 | 32 | 35 | 96 |
| Male | 25 | 18 | 17 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 3 | 4 |
| Not Hispanic or Latino | 53 | 48 | 49 | 150 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 |
| Black | 0 | 0 | 0 | 0 |
| White | 53 | 50 | 51 | 154 |
| Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Nov 2023, 16 months.
Results were first posted in Oct 2025, 1 year 10 months after primary completion.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 16 months is below that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorolanib
EyePoint Pharmaceuticals, Inc.